fludarabine


Also found in: Wikipedia.

fludarabine

 [floo-dar´ah-bēn]
an adenine analogue and purineantimetabolite that inhibits DNA synthesis; administered intravenously as the phosphate salt as an antineoplastic agent in the treatment of chronic lymphocytic leukemia.

fludarabine

/flu·dar·a·bine/ (floo-dar´ah-bēn) an adenine analogue and purine antimetabolite used as the phosphate salt as an antineoplastic in the treatment of chronic lymphocytic leukemia.

fludarabine

an antimetabolite used to treat neoplasia.
indications It is prescribed in the treatment of patients with B cell chronic lymphocytic leukemia and as salvage therapy for non-Hodgkin's lymphoma and acute leukemias.
contraindications It should not be given to patients who are pregnant or hypersensitive to this drug or its components. Patients should be closely observed for signs of hematologic and nonhematologic toxicity (e.g., edema, fatigue, myalgias).
adverse effects It is a potent antineoplastic agent with potentially significant side effects. The side effects most often reported include myelosuppression, fever and chills, nausea, and vomiting.

fludarabine

A CYTOTOXIC anti-cancer drug. A brand name is Fludara.
References in periodicals archive ?
The study titled "A Phase I/II Study of Burixafor Plus Fludarabine and Cytarabine in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) " is an open-label study to determine the safety and efficacy of burixafor in combination with two chemotherapeutic agents, fludarabine and cytaribine and will enroll up to 15 patients.
A 47-year-old male underwent NMA allo-SCT (using fludarabine and total body irradiation (TBI) 1200 cGyl) from an HLA-identical sibling due to high-risk acute myeloblastic leukemia (AML).
A repeat bone marrow biopsy performed two months later was consistent with lymphoma and 2 more cycles of fludarabine therapy were initiated.
The new agent was approved specifically for patients with CLL that has not responded to fludarabine (Fludara) and alemtuzumab (Campath).
The research team also involving researchers from University of Sienna, Italy have found PBOX- 15 was more effective than the current medication, fludarabine, used to treat the disease and also killed CLL cells that were resistant to treatment.
Tests in the laboratory show the drug is equally effective in treating the cells of patients who respond poorly to the current treatment, fludarabine.
About half of the patients (59) in the study were refractory to both fludarabine and alemtuzumab.
The drug is currently not approved for the treatment of multiple sclerosis but is indicated for treating B-cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and who have failed fludarabine therapy.
3) The patient in our case was immune-compromised from fludarabine chemotherapy followed by high-dose prednisone therapy.
A humanized monoclonal antibody for treating B-cell chronic lymphocytic leukemia in people who have been treated with alkylating agents and have failed treatment with fludarabine.
The drug, called Campath, slows the growth of cancerous white blood cells and is used to help patients whose condition has failed to improve with an existing treatment called Fludarabine.
We describe a patient with B-CLL whose B cells expressed CD8, a predominantly T-cell marker also expressed in natural killer cells, and we propose that patients with this uncommon feature of B-CLL might have an increased sensitivity to fludarabine phosphate, a substance recently often used to treat patients with CLL.